KJX839 Clinical Trials (2026): 1 Studies for Hypercholesterolaemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 KJX839 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Hypercholesterolaemia) and 520 total planned enrollment. 1 KJX839 clinical trial is actively recruiting. Most recent activity: NCT06501443 (Nov 2026).
KJX839 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P4 | 1 | 1 |
Recruiting KJX839 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06501443 | LATAM LOWERS LDL-C | P4 | Hypercholesterolaemia | 520 | Feb 2025 |
All KJX839 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06501443 | LATAM LOWERS LDL-C | P4 | recruiting | 520 | Novartis Pharmaceuticals | Feb 2025 |
KJX839 clinical trials: frequently asked questions
- How many KJX839 clinical trials are there?
- 1 KJX839 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are KJX839 clinical trials recruiting in 2026?
- Yes — 1 KJX839 trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is KJX839 being studied for?
- KJX839 is being studied for Hypercholesterolaemia. The trials are grouped by indication on this page.
- What phase is KJX839 in?
- KJX839 clinical trials span 1 Phase 4. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors KJX839 clinical trials?
- The lead sponsor across the most KJX839 trials is Novartis Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming KJX839as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: